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ABSTRACT Equilibrium binding ligands usually increase protein thermal stability by an amount proportional to the concentration
and afﬁnity of the ligand. High-throughput screening for the discovery of drug-like compounds uses an assay based on thermal
stabilization. The mathematical description of this stabilization is well developed, and the method is widely applicable to the
characterization of ligand-protein binding equilibrium. However, numerous cases have been experimentally observed where equi-
librium binding ligands destabilize proteins, i.e., diminish proteinmelting temperature by an amount proportional to the concentration
and afﬁnity of the ligand. Here, we present a thermodynamic model that describes ligand binding to the native and unfolded
(denatured) protein states explaining the combined stabilization and destabilization effects. The model also explains nonsaturation
and saturation effects on the protein melting temperature when the ligand concentration signiﬁcantly exceeds the protein con-
centration.Several examplesof theapplicability of themodel arepresented, includingspeciﬁc sulfonamidebinding to recombinant hCAII,
peptide and ANS binding to the Polo-box domain of Plk1, and zinc ion binding to the recombinant porcine growth hormone. The same
ligands may stabilize and destabilize different proteins, and the same proteins may be stabilized and destabilized by different ligands.
INTRODUCTION
The pharmaceutical industry uses a number of different
methods to measure drug candidate ligand binding to target
proteins of therapeutic interest. One of the main methods with
wide applicability and generality is the thermal shift assay (1),
also called ThermoFluor (2,3). This method is used in high-
throughput screening of chemical compounds to search for
strongly binding ligands that could be developed into thera-
peutic compounds (4). The ThermoFluor method has been
used to discover compounds that inhibit protein-protein in-
teraction, such as Hdm2-p53 interaction (5–7), and to mea-
sure ligand binding constants for enzymes such as carbonic
anhydrase (8,9). In addition, the method is useful for the
characterization of recombinant protein stability in various
solutions and in the presence of various excipients (10–12), the
optimization of conditions for protein crystallization (13), and
the determination of the function of unknown proteins (14).
The thermodynamic model for estimating binding con-
stants (9) is based on standard models from protein studies
with differential scanning calorimetry (15). The method is
based on the observation that ligands perturb protein thermal
stability upon binding to the protein in its native state. How-
ever, the major limitation of this model is that it does not
account for ligand binding to the unfolded state of a protein
during the thermal shift assay.
Most ligands stabilize proteins upon binding, causing an in-
crease in the protein melting temperature. Since most drug
candidates are stabilizers, the model is well developed to quan-
titatively account for the dependence of the stabilization on
ligand and protein concentrations (9). However, some ligands
destabilize proteins by binding primarily to the unfolded state
of theprotein anddestabilizing it (i.e., reduce theproteinmelting
temperature). Ligands that stabilize proteins may be called
N-binders (N-ligands, upshifters), and ligands that destabilize
proteins may be called U-binders (U-ligands, downshifters).
Here, we present a model that takes into account ligand
binding not only to the native state but also to the unfolded
state of the protein and develop a quantitative description of
protein destabilization by ligands. The dependence of protein
stabilization and destabilization on the thermodynamic
parameters of protein stability and ligand binding to two
different states is presented. Simulated dependencies are
presented for the enthalpy of unfolding, heat capacity of un-
folding, Gibbs free energy of ligand binding, enthalpy of
ligand binding, and protein concentration. Experimental ex-
amples that illustrate stabilization-destabilization events for
proteins and ligands of biochemical or pharmaceutical sig-
niﬁcance are described.
MATERIALS AND METHODS
Production of recombinant porcine
growth hormone
Escherichia coli strain BL21 (DE3) harboring a pET21a1-based expression
vectorwas used for recombinant porcine growth hormone (rpGH) production.
The vector contained a strong phage T7 promoter and a nucleotide sequence
encoding porcine growth hormone (pGH) (16).E. coli cells were cultivated in
a batch fermentation process previously described (17). Expression of the
target protein was induced with 1 mM isopropyl-1-thio-b-D-galactopyrano-
side (IPTG). rpGHwas expressed as an insoluble protein and accumulated in
the inclusion bodies. pGHwas refolded from solubilized inclusion bodies by a
dilution protocol in the presence of the glutathione pair at a ﬁnal concentration
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of 11.3 mM and pH 9.0. The (reduced glutathione)/(oxidized glutathione)
ratio was 2:1. The renatured protein was puriﬁed by ion-exchange chroma-
tography on Q-Sepharose followed by hydrophobic chromatography on
Phenyl-Sepharose (17,18). A ﬁnal protein solution in 25 mMTris-HCl buffer
pH 8.5 was frozen and stored at 20C. The rpGH biological activity was
determined in vitro on oGHR-FDC-P1 cells, as previously described (19,20).
Production of recombinant human
carbonic anhydrase II
Complementary DNA (cDNA) of human carbonic anhydrase II (hCAII) was
purchased from RZPD Deutsches Ressourcenzentrum fu¨r Genomforschung
(Berlin, Germany). For recombinant protein expression, a nucleotide se-
quence encoding full-length (hCAII (amino acids 1–260)) was inserted into
the pET-15b vector (Novagen,Madison,WI) via theNcoI andXhoI sites. The
cloning procedure resulted in the removal of the His-tag sequence, enabling
production of untagged hCAII construct.
For protein expression, the plasmid pET-15b-hCAII was transformed into
E. coli strain BL21 (DE3). An overnight culture of plasmid-harboring cells was
inoculated into fresh Luria-Bertani (LB) medium containing 60mMZnCl2 and
cultured at 37C until an A550 of 0.5–0.8 was reached. Expression of the target
protein was induced by 0.2mM IPTG. Cells cultured at 30C in the presence of
0.4 mM ZnCl2 were harvested 4 h after induction and lysed by sonication.
Soluble protein was puriﬁed using a Sepharose-IDA-Ni12 afﬁnity column,
followed by anion exchange chromatography on CM-Sepharose (Amersham
Biosciences, Uppsala, NY). Eluted protein was dialyzed into a storage buffer
(20 mM HEPES (pH 7.8), 0.05 M NaCl, and 0.2 mM dithiothreitol (DTT)),
lyophilized, and stored at 20C. The purity of hCAII preparations was ana-
lyzed by sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and determined to be higher than 95%. Protein concentrations were
determined by ultraviolet-visible (UV-Vis) spectrophotometry using the ex-
tinction coefﬁcient e280 ¼ 50,420 M1cm1 and conﬁrmed by the standard
Bradfordmethod. The catalytic activity of puriﬁed hCAII wasmeasured in a 10
mMHEPES (pH 7.5), 50 mMNa2SO4 buffer, containing 10% acetonitrile (the
standard buffer), using p-nitrophenyl acetate as a substrate (21). The enzyme
activity was conﬁrmed to be in the range of 1300–1400 pmol/(min3mg).
Production of recombinant Plk1-PBD
cDNA of human Polo-like kinase 1 (Plk1) was purchased from RZPD
Deutsches Ressourcenzentrum fu¨r Genomforschung (Berlin, Germany). For
the expression of the Polo-box domain (PBD) of Plk1, a nucleotide sequence
corresponding to the C-terminal part of the protein (amino acids 326–603)
was ampliﬁed by polymerase chain reaction (PCR) and inserted into a
pSUMO prokaryotic expression vector (LifeSensors, Malvern, PA) via the
Eco31I andHindIII sites. As a result, a His-tag containing SUMOproteinwas
fused to the N-terminus of Plk1-PBD.
For protein expression, plasmid pSUMO-Plk1-PBDwas transformed into
the E. coli strain Rosetta-gami 2 (DE3) (Novagen, Madison, WI). An over-
night culture of plasmid-harboring cells was inoculated into fresh LB me-
dium, cultured at 37Cuntil anA550 of 0.5–0.6, and put on ice. In the evening,
expression of the target protein was induced by 0.1 mM IPTG. After the
addition of IPTG, cells were cultured at 20C overnight, harvested by cen-
trifugation, and lysed by sonication in a buffer containing 20mMHEPES (pH
7.0), 0.2 M NaCl, 0.1 M imidazole, 2 mM b-mercaptoethanol, 0.1% thio-
glycerol, and complete EDTA-free protease inhibitor cocktail (Roche Ap-
plied Science, Indianapolis, IN). Soluble protein was puriﬁed using a
Sepharose-IDA-Ni12 afﬁnity column and dialyzed against buffer containing
20 mM Tris-HCl (pH 8.0), 150 mM NaCl, and 2.0 mM DTT for 24 h.
Cleavage of the SUMO-tag was performed at 4C overnight, using 1 unit of
SUMOprotease (LifeSensors,Malvern, PA) per 100mgof SUMO-Plk1-PBD
fusion protein. SUMO, and Plk1-PBD proteins were separated on a Sephar-
ose-IDA-Ni12 afﬁnity column. Eluted Plk1-PBD protein was dialyzed into a
storage buffer containing 50mMTris-HCl (pH 7.8), 0.2MNaCl, and 2.0mM
DTT, ﬂash frozen in liquid nitrogen, and stored at 80C. The purity of the
Plk1-PBD preparations was analyzed by SDS-PAGE and determined to be
higher than 95%. Protein concentrations were determined by UV-Vis spec-
trophotometry using the extinction coefﬁcient e280 ¼ 36,245 M1cm1 and
conﬁrmed by the standard Bradford method.
Carbonic anhydrase inhibitors
Standard carbonic anhydrase inhibitors, AZM (acetazolamide), CARBS
(p-carboxybenzene sulfonamide), and EZA (ethoxazolamide) were purchased
from Aldrich Chemical Co. (Milwaukee, WI). TFMSA (triﬂuoromethanesul-
fonamide) was purchased from Alfa Aesar (Karlsruhe, Germany). The ther-
modynamics of binding of these inhibitors have been previously described
(9,22). Inhibitor 3d (3-methylsulfonylbenzimidazo[1,2-c][1,2,3]thiadiazole-7-
sulfonamide) was synthesized as previously described (23).
Peptides for Plk1-PBD
For Plk1-PBD-ligand binding studies, the phosphopeptide PMQS-pT-PL,
representing the core of the optimal Polo-box binding ligand (24) and its
unphosphorylated counterpart PMQS-T-PLwere synthesized by JPT Peptide
Technologies (Berlin, Germany).
Thermal-shift assay (ThermoFluor)
The thermal shift assay was performed using the iCycler iQ Real Time
Detection System (Bio-Rad, Hercules, CA), originally designed for PCR.
Protein unfolding was monitored by measuring the ﬂuorescence of the sol-
vatochromic ﬂuorescent dye Dapoxyl sulfonic acid sodium salt. A temper-
ature increment of 1/min was applied. Samples contained 10–40 mM
protein, 0–4 mM ligand, and 50mMDapoxyl sulfonate in the total volume of
10 ml, overlayed with 2.5 ml of silicone oil DC 200; 96-well iCycler iQ PCR
plates were used for the assay.
RESULTS
Derivation of protein melting temperature Tm
versus ligand concentration Lt
A ligand may bind to the native (N) and/or unfolded (U)
protein. If the ligand binds to the unfolded state more strongly
than to the native state, then the protein is destabilized by the
ligand. On the other hand, if the ligand binds to the native
form more strongly than to the unfolded state, then the pro-
tein is stabilized by the ligand. The binding reactions may be
shown as linked equilibria:
½UL 
KbU
LigandBinding toUnfolded Protein
½U1 ½L
KU
Protein Unfolding
½N1 ½L 
LigandBinding toNative Protein
KbN ½NL; (1)
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where ½UL is the concentration of the unfolded protein-ligand
complex, ½U is the concentration of unfolded free protein, ½L is
the concentration of free ligand, ½N is the concentration of
native free protein, and ½NL is the concentration of the native
protein-ligand complex. KU is the equilibrium constant of pro-
tein unfolding in the absence of ligand, assuming that there are
only two protein states at equilibrium. It may be expressed as
KU ¼ ½U½N: (2)
KbN and KbU are ligand binding constants to the native and
unfolded protein states, respectively:
KbN ¼ ½NL½N½L (3)
KbU ¼ ½UL½U½L: (4)
Equations for the conservation of mass of the total protein
(Pt) and total ligand (Lt) are
Pt ¼ ½N1 ½U1 ½NL1 ½UL (5)
Lt ¼ ½L1 ½NL1 ½UL: (6)
The fraction of the unfolded protein may be expressed as
fU ¼ ½U1 ½UL
Pt
: (7)
The system of Eqs. 2–7was solved to express the total added
ligand concentration as a function of fU; Pt; KU; KbN; and KbU:
Lt ¼ ðfU1KUðfU1ÞÞ
3
PtðKbN1KbUKUÞ
KUðKbUKbNÞ 1
1
KUKbU fUðKbN1KbUKUÞ
 
: (8)
However, this equation may be simpliﬁed by considering
that at the protein melting temperature, the fraction of unfolded
protein is equal to one half (fU ¼ 0:5), i.e., the concentrations
of the folded and unfolded protein species are equal. Then, we
obtain the relationship between the equilibrium constants and
total concentrations of the ligand and the protein:
Lt ¼ ð1KU TmÞ
3
Pt
2
KbN Tm1KbU TmKU Tm
KU TmðKbU Tm KbN TmÞ
1
1
KU TmKbU Tm KbN Tm
 
:
(9)
This equation is valid only for the condition where T ¼ Tm:
Here, the subscript Tmof each equilibrium constant denotes
the value of the appropriate constant at the temperature Tm:
To ﬁnd a relationship between total ligand concentration
and protein melting temperature, the dependence of the
equilibrium constant on temperature should be considered.
Assuming the temperature-independent heat capacity of un-
folding and binding, the temperature dependence of the
equilibrium constant is given by
KU ¼ eDUGT=RT ¼ eðDUHTTDUSTÞ=RT
¼ e DUHTr 1DUCpðTTrÞT DUSTr 1DUCplnðT=TrÞð Þð Þ

RT
; (10)
where DUGT; DUHT; DUST; and DUCp are the Gibbs free
energy, enthalpy, entropy, and heat capacity changes of
unfolding, respectively, and R is the universal gas constant.
The temperature Tr is the reference temperature of protein
melting without added ligand. The temperature dependence
of the native form binding constant is given by
KbN ¼ eDbNGT=RT ¼ eðDbNHTTDbNSTÞ=RT
¼ e DbNHT01DbNCpðTT0ÞT DbNST01DbNCplnðT=T0Þð Þð Þ

RT
; (11)
where DbNGT; DbNHT; DbNST; and DbNCp are the Gibbs free
energy, enthalpy, entropy, and heat capacity of ligand bind-
ing to the native state protein, respectively. The reference
temperature T0 is equal to 37 C: The temperature dependence
of the binding constant to the unfolded protein is given by
KbU ¼ eDbUGT=RT ¼ eðDbUHTTDbUSTÞ=RT
¼ e DbUHT01DbUCpðTT0ÞT DbUST01DbUCplnðT=T0Þð Þð Þ

RT
; (12)
where DbUGT; DbUHT; DbUST; and DbUCp are the Gibbs free
energy, enthalpy, entropy, and heat capacity of ligand bind-
ing to the unfolded state protein, respectively.
Substituting Eq. 9 with Eqs. 10–12 at T ¼ Tm; we obtain
the total required ligand concentration Lt to reach the protein
melting temperature Tm:
This equation describes the relationship among all thermo-
dynamic parameters of protein unfolding and ligand binding
to two protein states and relates the parameters to the total
protein and ligand concentrations. The model is valid only
when the binding stoichiometries to the native and unfolded
forms of the protein are equal to 1:1.
Equation 13 is quite complex and can be simpliﬁed with
the assumption that a ligand does not bind either to the native
Lt¼ 1e DUHTr 1DUCpðTmTr ÞTm DUSTr1DUCplnðTm=Tr Þð Þð Þ

RTm
 
3
Pt
2
e DbNHT01DbNCpðTmT0ÞTm DbNST01DbNCplnðTm

T0Þ
  
=RTm1e DbUHT01DbUCpðTmT0ÞTm DbUST01DbUCplnðTm=T0Þð Þð Þ

RTme DUHTr1DUCpðTmTr ÞTm DUSTr1DUCplnðTm=Tr Þð Þð Þ

RTm
e
 DUHTr1DUCpðTmTr ÞTm DUSTr1DUCplnðTm=Tr Þð Þð Þ

RTm e
 DbUHT01DbUCpðTmT0ÞTm DbUST01DbUCplnðTm=T0Þð Þð Þ

RTme DbNHT01DbNCpðTmT0ÞTm DbNST01DbNCplnðTm=T0Þð Þð Þ

RTm
 
2
664
1
1
e DUHTr 1DUCpðTmTr ÞTm DUSTr 1DUCplnðTm=TrÞð Þð Þ

RTme DbUHT01DbUCpðTmT0ÞTm DbUST01DbUCplnðTm=T0Þð Þð Þ

RTme DbNHT01DbNCpðTmT0ÞTm DbNST01DbNCplnðTm=T0Þð Þð Þ

RTm
#
:
(13)
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or to the unfolded form. If a ligand does not bind to an un-
folded protein (KbU/0) or binds to the unfolded state more
weakly than to the native state, and conditions KbU  KbN
and KUKbU  KbN are satisﬁed, then Eq. 9 simpliﬁes to
Lt ¼ KU Tm  1ð Þ
Pt
2KU Tm
1
1
KbN Tm
 
: (14)
This equation can be expressed in terms of thermodynamic
parameters:
Equations 14 and 15 were derived byMatulis et al. (9), where
a partial model was derived without considering ligand
binding to an unfolded protein.
The other limiting situation is that where a ligand does not
bind to the native protein (KbN/0) or where it binds to the
native form more weakly than to the unfolded one, so that
conditions KbU  KbN and KUKbU  KbN are satisﬁed.
Then, Eq. 9 simpliﬁes to
Lt ¼ 1 KU Tmð Þ
Pt
2
1
2
KbU TmKU Tm
 
: (16)
This equation may be expressed in terms of thermodynamic
parameters:
Equation 13 and its partial forms (Eqs. 15 and 17) are tran-
scendental for Tmand can be solved only numerically. The
Brent algorithm (25) was used in writing the function Tm ¼
f ðLtÞ; which numerically solves Eq. 13. The obtained nu-
merical functionwas ﬁt to the additional experimental data for
ligand concentration dependence on protein melting temper-
ature. The ﬁt was performed using the nonlinear Levenberg-
Marquardt algorithm. Most parameters (except two: DbNST0
and DbUST0) were set to reasonable values and/or ﬁxed.
Simulated Tm ¼ f(Lt) curve dependence on
thermodynamic parameters of unfolding
and binding
Figs. 1–5 show hypothetical protein melting temperature
(Tm) dependencies on hypothetical ligand concentration (Lt).
The curves were simulated according to Eq. 13 using the
following thermodynamic parameters, except where noted
otherwise: DUHTr ¼ 400 kJ=mol; DUCp ¼ 10 kJ=ðmol3
KÞ; DbNHT0 ¼ 20 kJ=mol; DbNCp ¼ 1:3 kJ=ðmol3KÞ;
DbUHT0 ¼ 20 kJ=mol; DbUCp¼ 1:3 kJ=ðmol3KÞ; Tm¼
60C; T0 ¼ 37C; KbN T0 ¼ 107 for N-binders and ap-
proaches 0 for U-binders, KbU T0/0 for N-binders and 10
7
for U-binders, and Pt ¼ 10mM:
Fig. 1 shows the curves of the function Tm ¼ f(Lt) simu-
lated using various enthalpies of protein unfolding. Ligands
that stabilize proteins upon binding are N-binders—they
raise the protein Tm—whereas ligands that bind more
strongly to the unfolded form and destabilize proteins are
U-binders—they diminish the protein Tm. When all other
parameters are equal, the U-binders are expected to have a
stronger effect on proteins than N-binders (Fig. 1). In other
words, the Tm is diminished to a greater extent for U-binders
than it is increased for N-binders. The reason for such a result
is a nonlinear relationship between DG and Tm. Equal addi-
tion to or subtraction from DG does not lead to an equal
change in Tm.
Fig. 2 shows the same curve dependence on the heat ca-
pacity of unfolding. Here, we see a similar effect—the impact
of U-binders on the protein Tm is greater than that for
N-binders. However, the overall effect of the heat capacity is
signiﬁcantly less than the effect of the enthalpy (Fig. 1).
Fig. 3 compares the same curves at different binding con-
stants to the native (N-binders) and unfolded (U-binders)
forms. Stronger binding leads to a greater impact on the Tm.
However, the effect of U-binders is greater than the effect of
N-binders.Therefore, it takes less ligand-U-binder to reduce the
Tm by the same amount that the ligand-N-binder raises the Tm.
Fig. 4 compares the same curve dependence on the en-
thalpy of binding to the native and unfolded forms. The
difference between the binding enthalpies of 0 and 40 kJ/
mol, a range of realistic ligand binding enthalpies, is not very
large. However, different binding enthalpies may lead to an
error in the Tm of 3C–4C.
Fig. 5 illustrates the expected curve dependence if the
experiment is carried out at different protein concentrations.
Lt ¼ e DUHTr1DUCpðTmTrÞTm DUSTr1DUCplnðTm=TrÞð Þð Þ

RTm  1
 
3
Pt
2
1
e
 DUHTr 1DUCpðTmTrÞTm DUSTr 1DUCplnðTm=TrÞð Þð Þ

RTm
1
1
e
 DbNHT0 1DbNCpðTmT0ÞTm DbNST0 1DbNCplnðTm=T0Þð Þð Þ

RTm
" #
: (15)
Lt ¼ 1 e DUHTr1DUCpðTmTrÞTm DUSTr1DUCplnðTm=TrÞð Þð Þ

RTm
 
3
Pt
2
1
1
e
 DUHTr1DUCpðTmTrÞTm DUSTr1DUCplnðTm=TrÞð Þð Þ

RTme
 DbUHT01DbUCpðTmT0ÞTm DbUST01DbUCplnðTm=T0Þð Þð Þ

RTm
" #
: (17)
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At greater protein concentrations, the curves become more
sigmoidal, since it is expected to take more ligand to raise the
Tm to the same extent.
Experimental illustration of N-binders
and U-binders
Fig. 6 shows experimental temperature denaturation curves
of the Plk1-PBD protein with various added ligands. The
midpoint of the transition without any ligand (42C) is equal
to the Tm of the protein. The experimental data were ﬁt to the
unfolding model as in Matulis et al. (9). U-binder ligand
(ANS, 1,8-anilinonaphthalene sulfonate) addition shifted the
Tm downward, whereas the addition of a speciﬁc binding
peptide shifted the Tm upward.
Stabilization of carbonic anhydrase
Plotting the various ligand effects on protein Tm as a function
of the total added ligand concentration gives the Tm ¼ f(Lt)
functions. Fig. 7 shows the effect of three N-binders (stabi-
lizers) on the Tm of carbonic anhydrase II. These speciﬁc
sulfonamide inhibitors bind with 1:1 stoichiometry to the
active site of the enzyme. The curves, drawn according to
Eq. 13, match the experimental data points reasonably well.
FIGURE 3 Simulated dependence of the protein melting temperature Tm
on the concentration of ligand interacting with the following binding
constants (37C)—narrow dashed line: KbN or KbU ¼ 108 M1, bold solid
line: KbN or KbU ¼ 107 M1, bold dashed line: KbN or KbU ¼ 106 M1. For
N-binders, KbU/ 0, and for U-binders, KbN/ 0.
FIGURE 4 Simulated dependence of the protein melting temperature Tm
on the concentration of ligand interacting with the following binding
enthalpies (DbNH for N-binders and DbUH for U-binders)—narrow dashed
line: 0 kJ/mol, bold solid line: 20 kJ/mol, bold dashed line: 40 kJ/mol.
Other parameters were kept constant as explained in the Materials and
Methods section.
FIGURE 2 Simulated dependence of the protein melting temperature Tm
on added ligand concentration for proteins with different heat capacities of
unfolding (DuCp)—narrow dashed line: 15 kJ/(mol3 K), bold solid line: 10
kJ/(mol 3 K), and bold dashed line: 6.3 kJ/(mol 3 K), while keeping other
parameters constant. Ligand stabilizers shift the Tm upward, whereas ligand
destabilizers shift it downward.
FIGURE 1 Simulated dependence of the protein melting temperature
Tm on ligand concentration. Ligand stabilizers (N-binders) shift the Tm up-
ward, whereas ligand destabilizers (U-binders) shift the Tm downward.
Curves simulated for proteins with different enthalpies of unfolding (DUHTr ;
while keeping other parameters constant as described in Materials and
Methods)—narrow dashed line: 300 kJ/mol, bold solid line: 500 kJ/mol, and
bold dashed line: 700 kJ/mol.
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A slight discrepancy at the middle of the graph can be ex-
plained by the inexactness of the concentration of ligand or
protein. Compounds that bind more strongly raise the Tm to a
greater extent than the weaker binders. These results are
similar to our previous results (9).
Stabilization and destabilization of Plk1-PBD
The recombinant Polo-box domain Plk1-PBD binds the
phosphorylated peptide PMQS-pT-PL with a stoichiometry
of 1:1 and a binding constant of KbN (37C) ¼ 2.3 3 105
M1. However, the nonphosphorylated peptide PMQS-T-PL
did not bind the protein, and its KbN was nondetectable.
The same protein may exhibit thermal destabilization in
the presence of ligands that bind to the unfolded state more
strongly than to the native state. A good example of such
destabilization is ANS binding to Plk1-PBD. The addition of
ANS at concentrations comparable to the concentration of the
phosphorylated peptide in Fig. 8 produced a comparable
FIGURE 6 Temperature denaturation proﬁles of Plk1-PBD (10 mM).
Black-ﬁlled symbols represent the denaturation proﬁle of Plk1-PBD without
added ligand. Addition of the ligand ANS (open symbols) destabilized the
protein, shifting the Tm downward, whereas the addition of the phosphor-
ylated peptide (gray solid symbols) stabilized the protein, shifting its Tm
upward. The concentrations of the ligands: (triangles) 15.6 mM peptide and
31.3 mM ANS, (circles) 100 mM, (squares) 1000 mM. Data points are
experimental observations; the lines are simulated according to the model of
Eq. 13. The denaturation parameters of free Plk1-PBD were Tm ¼ 43:28C
and DUHTr ¼ 330 kJ=mol:
FIGURE 7 Dependence of the hCAII melting temperature on ligand
concentration: AZM (d), 3d (n), and CARBS (n). Lines are drawn
according to the model of Eq. 13. Regressed values of ligand binding
constants (KbN T0 ) are 63 10
6; 83 105; and 2:53 105 for AZM, 3d, and
CARBS, respectively.
FIGURE 5 Simulated dependence of the protein melting temperature Tm on
added ligand concentration Lt for various protein concentrations—Pt: narrow
dashed line: 3mM, bold solid line: 10mM, and bold dashed line: 30mM.Other
parameters were kept constant as explained in Materials and Methods.
FIGURE 8 Dependence of the Plk1-PBD melting temperature on the
concentration of added peptide in two forms: phosphorylated (n) and
unphosphorylated (n). Lines are drawn according to the model of Eq. 13,
using the following parameters: DUHTr ¼ 330 kJ=mol; DbNHT0 ¼
42 kJ=mol; Tr ¼ 43C; DUCp Tr ¼ 6:3 kJ=ðmol3KÞ; and DbNCp T0 ¼
1:3 kJ=ðmol3KÞ: For phosphorylated peptide, the binding constant was
KbN ¼ 2:33 105 M1. The unphosphorylated peptide binding constant was
nondetectable (KbN  102 M1).
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destabilization of the protein. Addition of 1 mM phosphor-
ylated peptide stabilized the protein by ;10C, whereas
addition of 1 mM ANS destabilized the protein by ;10C
(Fig. 9). Several representative curves of ﬂuorescence de-
pendence on temperature are shown in Fig. 6 for both sta-
bilization and destabilization.
Zinc binding to the growth hormone
Another important example of protein destabilization by
ligands is the binding of Zn21 to rpGH. Our results show that
zinc binds with the stoichiometry of one zinc cation per one
hormone molecule, resulting in signiﬁcant destabilization of
the protein. For example, the addition of 100 mM Zn21 de-
creased the melting temperature of the protein by ;10C
(Fig. 10). There was little difference between the zinc chlo-
ride and sulfate, indicating that only the cation is important
for this interaction. The binding constants to the unfolded
state of the rpGH were 1.6 3 106 M1 for zinc chloride and
2.3 3 106 M1 for zinc sulfate. Therefore, the Zn21 binding
constant to unfolded rpGH (KbU, 37C) was equal to (2.0 6
0.5) 3 106 M1. Other metals such as nickel and cobalt also
destabilized the rpGH. However, their binding constants and
destabilizing effects were signiﬁcantly smaller than z.
Zinc preferentially binds to the unfolded state of the rpGH
and destabilizes it. The binding constant for the unfolded form
is greater than the binding constant for the native form, which
is poorly determined by the method. The KbN is somewhere
between 0 and 104M1 and is hidden by the dominatingKbU.
Saturation effect
The model described by Eqs. 9 and 13 helps to explain the
saturation effect. The saturation effect is a term we have used
to describe the situation where the addition of ligand in-
creases the Tm by a lesser extent than expected based on its
binding afﬁnity. It was often observed that the addition of
ligands did not increase the melting temperature to the extent
predicted by our previous models, which did not account for
ligand binding to the unfolded state. For example, the binding
of EZA and TFMSA to carbonic anhydrase exhibits the
saturation effect (Fig. 11). At submillimolar concentrations,
the ligands do not shift the Tm to the extent predicted by the
FIGURE 9 Dependence of Plk1-PBD melting temperature on ANS con-
centration. Lines are drawn according to the model of Eq. 13 using the
following parameters: DUHTr ¼ 330 kJ=mol; DbUHT0 ¼ 10 kJ=mol; Tr ¼
43 C; DUCp Tr ¼ 6:3 kJ=ðmol3KÞ; and DbNCp T0 ¼ 0:8 kJ=ðmol3KÞ:
The binding constant is KbU T0 ¼ 1:53 104 M1:
FIGURE 10 Dependence of the rpGH melting temperature on added metal
concentration: CoCl2 (:), NiCl2 (n), ZnCl2 (¤), and ZnSO4 (n). Lines are
drawn according to themodel of Eq. 13. The following parameterswere used to
obtain binding constants to unfolded rpGH:DUHTr ¼ 630 kJ=mol; DbUHT0 ¼
5 kJ=mol; Tr ¼ 65C; DUCp Tr ¼ 10 kJ=ðmol3KÞ; and DbNCp T0 ¼
1:3 kJ=ðmol3KÞ: The binding constants KbU T0 for CoCl2, NiCl2, ZnCl2,
and ZnSO4 are equal to 23 10
4; 43 104; 1:63 106; and 2:33 106 M1,
respectively.
FIGURE 11 Dependence of the recombinant human carbonic anhydrase II
melting temperature on the total added concentration ofEZA (h) andTFMSA
(:). Dashed lines represent the ﬁt assumingKbU/ 0, Eq. 15, whereas solid
lines are ﬁt using Eq. 13. For vanishing KbU; the ﬁtted KbN constants have
values of 13108 and 83106 M1 for EZA and TFMSA, respectively. The
binding constants (under the condition when KbU was allowed to vary) are as
follows: KbN ¼ 1:293108 and KbU ¼ 1:243105 M1 for EZA, and KbN ¼
9:243106 and KbU ¼ 2:823104 M1 for TFMSA.
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model. At ;200 mM, the Tm is ;2C lower than predicted,
which does not account for the ligand binding to the unfolded
state of the protein (dashed line, Fig. 11). However, the ap-
plication of our model that does account for the ligand
binding to the unfolded state shows a model curve (solid line,
Fig. 11) that ﬁts the experimental data much better.
Fitting of the experimental data to the previousmodel (Eqs.
14 and 15) yielded the binding constants (Kb, 37C) of 1.03
108 M1 for EZA and 8.03 106 M1 for TFMSA. However,
application of the full model (Eqs. 9 and 13) yielded the fol-
lowing binding constants (37C): KbN ¼ 1:33 108 M1,
KbU ¼ 1:23 105 M1 for EZA and KbN ¼ 9:23 106 M1,
KbU ¼ 2:83 104 M1 for TFMSA. The application of both
models yields similar binding constants for the native state.
However, the new model, which accounts for the binding to
the denatured state of the protein, fully accounts for the sat-
uration effect and determines the binding to the denatured
state of the protein.
DISCUSSION
This model, which takes into account ligand binding to both
the native and denatured protein states, is more detailed than
the previously described model (9), helps to quantitatively
account for protein destabilization by ligands, and determines
the ligand binding constant to both protein states. As shown
with several examples of unrelated proteins and ligands,
some proteins may be stabilized or destabilized by various
ligands. The destabilization effect is often hidden, since most
ligands stabilize proteins upon their speciﬁc binding with 1:1
stoichiometry to sites such as the enzyme active site.
Ligand binding to the unfolded protein state is not well
understood. There are no crystal structures of any unfolded
proteins. We do not know exact sites of ANS binding to
unfolded Plk1-PBD or Zn21 binding to unfolded pGH, for
example. However, the U-binder effect is obvious and indi-
cates strong binding to the unfolded state.
An important implication of this model is that the binding
constants routinely determined by the thermal shift assay
may be incorrect. They may be lower than the constants
determined by methods where the temperature is not raised
and no denaturation occurs, such as isothermal titration calo-
rimetry. If, for example, the Kb (37C) by isothermal titration
calorimetry (ITC) is determined to be equal to 107 M1 and
theKbN (extrapolated to 37C) by thermal shift is equal to 107
M1, then we can be quite certain that we have determined
the actual Kb (37C). However, if we determine the KbN only
by the thermal shift assay, then there is no certainty that it is
really equal to Kb (37C), since the actual Kb may be greater
than KbN if there is a signiﬁcant KbU. However, the actual Kb
cannot be smaller than KbN. Therefore, the hits obtained by
the thermal shift assay are real and the method is valid. In
short, the thermal shift assay may somewhat underestimate
the binding constant for the native state. The method, how-
ever, will not overestimate the constant.
A limitation of the model is that it assumes that there is
only one unfolded state of the protein. It is likely that an
unfolded protein exists in a large number of semiﬂexible
conformational states. The model approximates the unfolded
state of the protein as a single thermodynamic state. Another
limitation is that the model analyzes binding as having 1:1
stoichiometry. In the case of U-binders, it is possible that a
number of ligand molecules bind to the unfolded state with
variable potency. A cumulative effect would probably be
observed where several weakly binding ligands shift the Tm
as much as one strongly binding ligand. Such cases would
have to be analyzed by a signiﬁcantly more complex model.
Stabilization of carbonic anhydrase
Inhibitors that bind speciﬁcally, such as sulfonamides, bind
to the active site of the enzyme carbonic anhydrase with a
stoichiometry of 1:1. Such inhibitors bind strongly to the
native state protein and bind weakly, if at all, to the unfolded
state of the protein. Therefore, inhibitor binding to carbonic
anhydrase is well approximated by Eq. 15, where it is as-
sumed that KbU is negligible (KbU/0) or the binding to the
unfolded state is weaker than to the native state and condi-
tions KbU  KbN and KUKbU  KbN are satisﬁed. Since all
these conditions are met for inhibitor binding to carbonic
anhydrase, the approximation is valid and the binding con-
stants match those obtained by isothermal titration calorim-
etry, as previously discussed (9).
However, some strong carbonic anhydrase inhibitors, such
as EZA and TFMSA (Fig. 11), exhibit nonlinear Tm depen-
dence on ligand concentration (on a semilogarithmic scale).
First, we discuss the reason for the expected linearity of the
dependence, since there is a misconception that it results from
the bonds formed between the ligand and protein and holds
the protein in a more stable conformation. As previously
discussed (26), it is important to note that the Tm shift caused
by the ligand continues with increasing ligand concentration
beyond the levels where the protein is fully saturated with
ligand. The contribution from the entropy of mixing is
dominant here. Enhanced stability arises from the additional
Gibbs free energy required to remove the ligand from the
protein before its unfolding, and this free energy has an im-
portant component arising from the entropy of mixing of
dissociated ligand and depends on the concentration of free
ligand in solution.
In addition to numerous examples where the protein Tm
increases linearly with increasing concentration (e.g., Figs. 7,
8, and 9), there are examples where the Tm stops increasing
(e.g., Fig. 11, and an example of Ca21 binding to a-lactal-
bumin (26)). It has been suggested that saturation may be
caused either by ligand binding to the unfolded state of the
protein (26) or by the low solubility of the ligand (9). Both
these reasons may cause the saturation effect. However, in
the case of EZA and TFMSA binding to hCAII, ligand sol-
ubility is probably not the limiting factor, and the quantitative
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model, which takes into account ligand binding to the un-
folded state accounts for the experimental data remarkably
well (Fig. 11). Interestingly, the binding constants for the
unfolded state were only ;1000-fold weaker than those of
the folded state.
Stabilization and destabilization of Plk1-PBD
The Plk1 PBD is a good example of the same protein being
strongly stabilized and destabilized by various ligands. A
speciﬁcally binding phosphorylated peptide was a strong
stabilizer, whereas its unphosphorylated counterpart did not
affect the stability, and the negatively charged ANS was a
strong destabilizer. We do not know the mode or the exact
stoichiometry of ANS binding to the unfolded state, but the
data are consistent with the model of the stoichiometry of 1:1.
The thermal shift approach contributes data of peptide
binding to Plk1-PBD. This protein binds the phosphorylated
peptide PMQS-pT-PL with a stoichiometry of 1:1 and the
binding constant KbN ¼ 2.3 3 105 M1 (KdN ¼ 4.3 mM,
37C). However, the binding of unphosphorylated peptide
PMQS-T-PL was not detected. The literature lists contro-
versial numbers for binding. It was determined by ITC that
the peptide containing the same core (MAGPMQS-pT-
PLNGAKK) binds to Plk1-PBD with Kd ¼ 0.28 mM,
whereas the binding of the same unphosphorylated peptide is
undetectable (24). However, other authors determined by
tryptophan ﬂuorescence measurements that the binding of
both peptides was similar; the Kd for the phosphorylated
peptide was determined to be 2.77 mM, whereas the Kd of the
unphosphorylated peptide was equal to 3.53 mM (27). Our
results (Fig. 8) support the notion that the phosphorylation of
the threonine is essential for the binding of the peptide to
Plk1-PBD.
Zinc binding to the growth hormone
Zinc has been shown to be important for the function of
growth hormones from humans and other organisms. For
example, Zn21 has been demonstrated to enhance the activity
of human growth hormone (hGH) in a cell line based bio-
logical assay (28,29). The binding afﬁnity of hGH with the
extracellular binding domain of the human prolactin receptor
was increased ;8000-fold by the addition of 50 mM ZnCl2,
whereas Zn21 was not required for hGH binding to the hGH
receptor (30). Zinc has also been demonstrated to induce
dimerization of hGH, and the resulting Zn21-hGH dimer has
been proposed as the major storage form of hGH in vivo.
Mutational analysis indicated that His18, His21, and Glu174
participate in coordinating Zn21 and promoting formation of
the hormone dimer (31).
Porcine growth hormone (pGH) used in this study shares
68% sequence identity with hGH (32). Studies on porcine
growth hormone interaction with zinc are interesting from the
evolutionary point of view, since there are some major dif-
ferences between human and porcine growth hormones. For
example, hGH has lactogenic activity, but pGH has no lac-
togenic activity (33). Moreover, zinc-protein precipitates
may be useful for protein puriﬁcation, storage, and formu-
lation. Precipitation of hGH by zinc does not alter the sec-
ondary structure of hGH, and the process is fully reversible.
Zinc binding induces only minor tertiary structural changes
to the protein (34).
Our results on the interactions of rpGH with metals show
that there is a speciﬁc effect of zinc on the protein. Zinc
preferentially binds to the unfolded state of the rpGH and
destabilizes it. The binding constant for the unfolded form is
equal to;23 106 M1, whereas the binding constant for the
native form is poorly determined by this method. The KbN is
equal to somewhere between 0 and 104 M1, and it is hidden
by the dominating KbU. There may be more than one Zn
binding site in the U-state, but the consecutive binders, if any,
should have weaker binding constants.
Zinc binding to rpGH is another example of a ligand that
preferentially binds the unfolded state of the protein. Again,
we do not know the exact mode or the stoichiometry of zinc
binding to the unfolded protein. However, the model implies
that the binding stoichiometry is one Zn21 bound to one
rpGH molecule. The binding constant (Kd ¼ 0.5 mM) is
rather strong, implying that there is a speciﬁc Zn21-binding
site available only in the unfolded state of the protein.
CONCLUSIONS
The above examples of three protein systems illustrate the
applicability of the model of protein stabilization and desta-
bilization by ligands. To conclude, this model, which takes
into account ligand binding to both the native and denatured
protein states, is more detailed and helps to quantitatively
account for protein destabilization by ligands, determines the
ligand binding constants to both protein states, and helps to
explain the saturation effect.
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